3,14-Diacetyloxymorphone
A semi-synthetic opioid analgesic
| 3,14-Diacetyloxymorphone | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
3,14-Diacetyloxymorphone is a semi-synthetic opioid analgesic derived from oxymorphone. It is chemically related to other opioids such as morphine and heroin.
Chemical Structure[edit]
3,14-Diacetyloxymorphone is an acetylated derivative of oxymorphone, with acetyl groups at the 3 and 14 positions of the morphinan skeleton. This modification increases its lipophilicity, potentially enhancing its ability to cross the blood-brain barrier.
Pharmacology[edit]
As an opioid, 3,14-Diacetyloxymorphone acts primarily on the mu-opioid receptor, producing effects such as analgesia, euphoria, and respiratory depression. Its potency and efficacy are influenced by its chemical structure, which affects its binding affinity and intrinsic activity at opioid receptors.
Synthesis[edit]
The synthesis of 3,14-Diacetyloxymorphone involves the acetylation of oxymorphone. This process typically uses acetic anhydride as the acetylating agent in the presence of a catalyst or under specific conditions to ensure selective acetylation at the desired positions.
Medical Use[edit]
While 3,14-Diacetyloxymorphone itself is not commonly used in clinical practice, its parent compound, oxymorphone, is used for the management of moderate to severe pain. The acetylated derivative may have been studied for its pharmacokinetic properties or potential as a prodrug.
Legal Status[edit]
Due to its structural similarity to other controlled opioids, 3,14-Diacetyloxymorphone is likely to be regulated under similar legal frameworks. It may be classified as a controlled substance in many jurisdictions, subject to restrictions on its manufacture, distribution, and use.
Related pages[edit]
-
3,14-Diacetyloxymorphone
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian